Ignite Creation Date:
2025-12-24 @ 10:15 PM
Ignite Modification Date:
2026-04-07 @ 2:03 AM
Study NCT ID:
NCT00577135
Status:
COMPLETED
Last Update Posted:
2018-03-06
First Post:
2007-12-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006333', 'term': 'Heart Failure'}, {'id': 'D004487', 'term': 'Edema'}], 'ancestors': [{'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D049994', 'term': 'Sodium Potassium Chloride Symporter Inhibitors'}], 'ancestors': [{'id': 'D049990', 'term': 'Membrane Transport Modulators'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D020228', 'term': 'Pharmacologic Actions'}, {'id': 'D020164', 'term': 'Chemical Actions and Uses'}, {'id': 'D004232', 'term': 'Diuretics'}, {'id': 'D045283', 'term': 'Natriuretic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'jeff.sharp@dm.duke.edu', 'phone': '919.668.7086', 'title': 'Jeff Sharp', 'organization': 'Duke University'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'description': 'Only Serious Adverse Events were collected for this study', 'eventGroups': [{'id': 'EG000', 'title': 'Q 12 Hour Bolus', 'otherNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 156, 'seriousNumAffected': 69}, {'id': 'EG001', 'title': 'Continuous Infusion', 'otherNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 152, 'seriousNumAffected': 67}, {'id': 'EG002', 'title': 'Low Intensification', 'otherNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 151, 'seriousNumAffected': 76}, {'id': 'EG003', 'title': 'High Intensification', 'otherNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 157, 'seriousNumAffected': 60}], 'seriousEvents': [{'term': 'Cardiac Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 18}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 20}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 15}], 'organSystem': 'Cardiac disorders'}, {'term': 'Cardiac Failure Acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 10}], 'organSystem': 'Cardiac disorders'}, {'term': 'Ventricular Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 4}], 'organSystem': 'Cardiac disorders'}, {'term': 'Renal Failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 4}], 'organSystem': 'Renal and urinary disorders'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 11}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 5}], 'organSystem': 'Vascular disorders'}, {'term': 'Anemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders'}, {'term': 'Acute Myocardial Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Cardiac disorders'}, {'term': 'Cardiac Arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 3}], 'organSystem': 'Cardiac disorders'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 2}], 'organSystem': 'Infections and infestations'}, {'term': 'Renal Failure Acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders'}, {'term': 'Angina Pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Cardiac disorders'}, {'term': 'Atrial Fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Cardiac disorders'}, {'term': 'Atrial Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Cardiac disorders'}, {'term': 'Cardiac Failure Chronic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 2}], 'organSystem': 'Cardiac disorders'}, {'term': 'Cardiogenic Shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 0}], 'organSystem': 'Cardiac disorders'}, {'term': 'Myocardial Infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Cardiac disorders'}, {'term': 'Ventricular Arrhythmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 0}], 'organSystem': 'Cardiac disorders'}, {'term': 'Arterial Thrombosis Limb', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 0}], 'organSystem': 'Vascular disorders'}, {'term': 'Deep Vein Thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 0}], 'organSystem': 'Vascular disorders'}, {'term': 'Shock Haemorrhagic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 0}], 'organSystem': 'Vascular disorders'}, {'term': 'Renal Failure Chronic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders'}, {'term': 'Cerebrovascular Accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 1}], 'organSystem': 'Nervous system disorders'}, {'term': 'Hyperkalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 156, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 152, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 151, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 157, 'numAffected': 5}], 'organSystem': 'Metabolism and nutrition disorders'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Patient Well Being, as Determined by a Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '154', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}, {'value': '148', 'groupId': 'OG002'}, {'value': '155', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '4236', 'spread': '1440.4', 'groupId': 'OG000'}, {'value': '4372.7', 'spread': '1404.4', 'groupId': 'OG001'}, {'value': '4170.8', 'spread': '1436.3', 'groupId': 'OG002'}, {'value': '4429.6', 'spread': '1401.4', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Measured at 72 hours', 'description': 'Global Visual Analog Scale Scale Range 0-7200; higher score is better', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'PRIMARY', 'title': 'Change in Serum Creatinine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '155', 'groupId': 'OG000'}, {'value': '146', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '154', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.05', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '0.07', 'spread': '0.30', 'groupId': 'OG001'}, {'value': '0.04', 'spread': '0.29', 'groupId': 'OG002'}, {'value': '0.08', 'spread': '0.31', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Measured at baseline and 72 hours', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Weight', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}, {'value': '142', 'groupId': 'OG001'}, {'value': '141', 'groupId': 'OG002'}, {'value': '152', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '-8.0', 'spread': '7.8', 'groupId': 'OG000'}, {'value': '-9.1', 'spread': '10.2', 'groupId': 'OG001'}, {'value': '-7.4', 'spread': '10.1', 'groupId': 'OG002'}, {'value': '-9.6', 'spread': '7.9', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and 96 hours', 'unitOfMeasure': 'lbs', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Proportion of Patients Free of Congestion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'OG000'}, {'value': '144', 'groupId': 'OG001'}, {'value': '143', 'groupId': 'OG002'}, {'value': '154', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '14.4', 'groupId': 'OG000'}, {'value': '15.3', 'groupId': 'OG001'}, {'value': '11.2', 'groupId': 'OG002'}, {'value': '18.2', 'groupId': 'OG003'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Measured at 72 hours', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Dyspnea, as Determined by Visual Analog Scales', 'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '155', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '1370.8', 'spread': '486.0', 'groupId': 'OG000'}, {'value': '1453.8', 'spread': '518.0', 'groupId': 'OG001'}, {'value': '1426.0', 'spread': '504.5', 'groupId': 'OG002'}, {'value': '1398.2', 'spread': '502.7', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Measured at 24 hours', 'description': 'Global Visual Analog Scale Scale Range 0-2400; higher score is better', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Serum Creatinine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '154', 'groupId': 'OG000'}, {'value': '146', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '153', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.00', 'spread': '0.18', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.17', 'groupId': 'OG001'}, {'value': '-0.01', 'spread': '0.16', 'groupId': 'OG002'}, {'value': '0.02', 'spread': '0.19', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and 24 hours', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Cystatin C', 'denoms': [{'units': 'Participants', 'counts': [{'value': '125', 'groupId': 'OG000'}, {'value': '122', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}, {'value': '126', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.11', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '0.17', 'spread': '0.35', 'groupId': 'OG001'}, {'value': '0.12', 'spread': '0.35', 'groupId': 'OG002'}, {'value': '0.17', 'spread': '0.31', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and 72 hours', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Serum Creatinine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '155', 'groupId': 'OG000'}, {'value': '146', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '154', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.02', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.26', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.23', 'groupId': 'OG002'}, {'value': '0.06', 'spread': '0.25', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and 48 hours', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Serum Creatinine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '155', 'groupId': 'OG000'}, {'value': '146', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '154', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.06', 'spread': '0.32', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.32', 'groupId': 'OG001'}, {'value': '0.05', 'spread': '0.33', 'groupId': 'OG002'}, {'value': '0.07', 'spread': '0.31', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and 96 hours', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Serum Creatinine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '155', 'groupId': 'OG000'}, {'value': '146', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '154', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.10', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.32', 'groupId': 'OG001'}, {'value': '0.07', 'spread': '0.33', 'groupId': 'OG002'}, {'value': '0.08', 'spread': '0.40', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and day 7', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Serum Creatinine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '117', 'groupId': 'OG000'}, {'value': '116', 'groupId': 'OG001'}, {'value': '114', 'groupId': 'OG002'}, {'value': '119', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.09', 'spread': '0.41', 'groupId': 'OG000'}, {'value': '0.07', 'spread': '0.45', 'groupId': 'OG001'}, {'value': '0.09', 'spread': '0.43', 'groupId': 'OG002'}, {'value': '0.07', 'spread': '0.43', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and day 60', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Patient Well Being, as Determined by a Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '155', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '1280.8', 'spread': '469.7', 'groupId': 'OG000'}, {'value': '1303.0', 'spread': '465.1', 'groupId': 'OG001'}, {'value': '1288.6', 'spread': '455.9', 'groupId': 'OG002'}, {'value': '1294.8', 'spread': '478.4', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Measured at 24 hours', 'description': 'Global Visual Analog Scale Scale Range 0-2400; higher score is better', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Patient Well Being, as Determined by a Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '155', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '2722.6', 'spread': '940.0', 'groupId': 'OG000'}, {'value': '2792.6', 'spread': '932.7', 'groupId': 'OG001'}, {'value': '2706.5', 'spread': '931.5', 'groupId': 'OG002'}, {'value': '2805.2', 'spread': '939.8', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': '48 hours', 'description': 'Global Visual Analog Scale Scale Range 0-4800; higher score is better', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Dyspnea VAS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '155', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '2876.6', 'spread': '960.1', 'groupId': 'OG000'}, {'value': '3033.1', 'spread': '1039.3', 'groupId': 'OG001'}, {'value': '2924.9', 'spread': '1012.8', 'groupId': 'OG002'}, {'value': '2981.3', 'spread': '992.9', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': '48 hours', 'description': 'Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Dyspnea VAS', 'denoms': [{'units': 'Participants', 'counts': [{'value': '154', 'groupId': 'OG000'}, {'value': '149', 'groupId': 'OG001'}, {'value': '148', 'groupId': 'OG002'}, {'value': '155', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '4455.6', 'spread': '1468.4', 'groupId': 'OG000'}, {'value': '4699.1', 'spread': '1572.7', 'groupId': 'OG001'}, {'value': '4477.9', 'spread': '1549.7', 'groupId': 'OG002'}, {'value': '4668.3', 'spread': '1496.0', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': '72 hours', 'description': 'Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Cystatin C', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '131', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}, {'value': '137', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.21', 'spread': '0.43', 'groupId': 'OG000'}, {'value': '0.16', 'spread': '0.48', 'groupId': 'OG001'}, {'value': '0.16', 'spread': '0.48', 'groupId': 'OG002'}, {'value': '0.21', 'spread': '0.42', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and day 7', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Cystatin C', 'denoms': [{'units': 'Participants', 'counts': [{'value': '92', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '91', 'groupId': 'OG002'}, {'value': '99', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.20', 'spread': '0.51', 'groupId': 'OG000'}, {'value': '0.16', 'spread': '0.43', 'groupId': 'OG001'}, {'value': '0.18', 'spread': '0.47', 'groupId': 'OG002'}, {'value': '0.18', 'spread': '0.46', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and day 60', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Uric Acid', 'denoms': [{'units': 'Participants', 'counts': [{'value': '125', 'groupId': 'OG000'}, {'value': '121', 'groupId': 'OG001'}, {'value': '120', 'groupId': 'OG002'}, {'value': '126', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.30', 'spread': '1.02', 'groupId': 'OG000'}, {'value': '0.44', 'spread': '1.20', 'groupId': 'OG001'}, {'value': '0.11', 'spread': '1.01', 'groupId': 'OG002'}, {'value': '0.61', 'spread': '1.15', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and 72 hours', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Uric Acid', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '130', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}, {'value': '137', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '0.40', 'spread': '1.47', 'groupId': 'OG000'}, {'value': '0.09', 'spread': '1.96', 'groupId': 'OG001'}, {'value': '0.07', 'spread': '1.69', 'groupId': 'OG002'}, {'value': '0.42', 'spread': '1.75', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and day 7', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in Uric Acid', 'denoms': [{'units': 'Participants', 'counts': [{'value': '92', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}, {'value': '93', 'groupId': 'OG002'}, {'value': '98', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.09', 'spread': '2.28', 'groupId': 'OG000'}, {'value': '-0.71', 'spread': '2.27', 'groupId': 'OG001'}, {'value': '-0.13', 'spread': '2.33', 'groupId': 'OG002'}, {'value': '-0.67', 'spread': '2.24', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 60', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in B-type Natriuretic Peptide', 'denoms': [{'units': 'Participants', 'counts': [{'value': '124', 'groupId': 'OG000'}, {'value': '121', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}, {'value': '124', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '-1316.2', 'spread': '4364.3', 'groupId': 'OG000'}, {'value': '-1773.2', 'spread': '3827.5', 'groupId': 'OG001'}, {'value': '-1193.8', 'spread': '4094.1', 'groupId': 'OG002'}, {'value': '-1881.6', 'spread': '4105.4', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and 72 hours', 'description': 'Change in NTproBNP', 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in NTproBNP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '136', 'groupId': 'OG000'}, {'value': '130', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}, {'value': '135', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '-1133.3', 'spread': '4883.4', 'groupId': 'OG000'}, {'value': '-1552.0', 'spread': '4875.8', 'groupId': 'OG001'}, {'value': '-1037.2', 'spread': '5211.8', 'groupId': 'OG002'}, {'value': '-1629.7', 'spread': '4524.6', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 7', 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Change in NTproBNP', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}, {'value': '91', 'groupId': 'OG002'}, {'value': '98', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '-1449.3', 'spread': '5010.1', 'groupId': 'OG000'}, {'value': '-1035.1', 'spread': '6962.9', 'groupId': 'OG001'}, {'value': '-1445.6', 'spread': '5805.3', 'groupId': 'OG002'}, {'value': '-1038.5', 'spread': '6364.3', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 60', 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Presence of Cardiorenal Syndrome', 'denoms': [{'units': 'Participants', 'counts': [{'value': '155', 'groupId': 'OG000'}, {'value': '146', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '154', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '17.4', 'groupId': 'OG000'}, {'value': '19.2', 'groupId': 'OG001'}, {'value': '13.6', 'groupId': 'OG002'}, {'value': '22.7', 'groupId': 'OG003'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Within 72 hours', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Treatment Failure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '155', 'groupId': 'OG000'}, {'value': '147', 'groupId': 'OG001'}, {'value': '147', 'groupId': 'OG002'}, {'value': '155', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '38.1', 'groupId': 'OG000'}, {'value': '38.8', 'groupId': 'OG001'}, {'value': '36.7', 'groupId': 'OG002'}, {'value': '40.0', 'groupId': 'OG003'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Within 72 hours', 'description': 'Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Net Fluid Loss', 'denoms': [{'units': 'Participants', 'counts': [{'value': '150', 'groupId': 'OG000'}, {'value': '140', 'groupId': 'OG001'}, {'value': '141', 'groupId': 'OG002'}, {'value': '149', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '1595.7', 'spread': '1476.7', 'groupId': 'OG000'}, {'value': '1796.4', 'spread': '1685.1', 'groupId': 'OG001'}, {'value': '1209.7', 'spread': '1309.3', 'groupId': 'OG002'}, {'value': '2149.6', 'spread': '1681.7', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Through 24 hours', 'unitOfMeasure': 'mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Net Fluid Loss', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '136', 'groupId': 'OG001'}, {'value': '139', 'groupId': 'OG002'}, {'value': '145', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '2996.7', 'spread': '2490.5', 'groupId': 'OG000'}, {'value': '3120.6', 'spread': '2504.2', 'groupId': 'OG001'}, {'value': '2334.8', 'spread': '2006.4', 'groupId': 'OG002'}, {'value': '3747.4', 'spread': '2716.1', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Through 48 hours', 'unitOfMeasure': 'mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}, {'type': 'SECONDARY', 'title': 'Net Fluid Loss', 'denoms': [{'units': 'Participants', 'counts': [{'value': '129', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '120', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Q 12 Hour Bolus'}, {'id': 'OG001', 'title': 'Continuous Infusion'}, {'id': 'OG002', 'title': 'Low Intensification'}, {'id': 'OG003', 'title': 'High Intensification'}], 'classes': [{'categories': [{'measurements': [{'value': '4236.7', 'spread': '3207.6', 'groupId': 'OG000'}, {'value': '4249.2', 'spread': '3104.3', 'groupId': 'OG001'}, {'value': '3575.2', 'spread': '2634.8', 'groupId': 'OG002'}, {'value': '4898.9', 'spread': '3478.5', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Through 72 hours', 'unitOfMeasure': 'mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Q12 Hours Bolus & Low Intensification', 'description': 'Low intensification (1 x oral dose) IV furosemide by Q12 hours bolus'}, {'id': 'FG001', 'title': 'Q12 Hours Bolus & High Intensification', 'description': 'High intensification (2.5 x oral dose) IV furosemide by Q12 hours bolus'}, {'id': 'FG002', 'title': 'Continuous Infusion & Low Intensification', 'description': 'Low intensification (1 x oral dose) IV furosemide by continuous infusion'}, {'id': 'FG003', 'title': 'Continuous Infusion & High Intensification', 'description': 'High intensification (2.5 x oral dose) IV furosemide by continuous infusion'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '74'}, {'groupId': 'FG001', 'numSubjects': '82'}, {'groupId': 'FG002', 'numSubjects': '77'}, {'groupId': 'FG003', 'numSubjects': '75'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '74'}, {'groupId': 'FG001', 'numSubjects': '82'}, {'groupId': 'FG002', 'numSubjects': '77'}, {'groupId': 'FG003', 'numSubjects': '75'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'BG000'}, {'value': '82', 'groupId': 'BG001'}, {'value': '77', 'groupId': 'BG002'}, {'value': '75', 'groupId': 'BG003'}, {'value': '308', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'Q12 Hours Bolus & Low Intensification'}, {'id': 'BG001', 'title': 'Q12 Hours Bolus & High Intensification'}, {'id': 'BG002', 'title': 'Continuous Infusion & Low Intensification'}, {'id': 'BG003', 'title': 'Continuous Infusion & High Intensification'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '67.4', 'spread': '12.4', 'groupId': 'BG000'}, {'value': '65.2', 'spread': '13.8', 'groupId': 'BG001'}, {'value': '64.5', 'spread': '14.1', 'groupId': 'BG002'}, {'value': '67.2', 'spread': '14.0', 'groupId': 'BG003'}, {'value': '66.0', 'spread': '13.6', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}, {'value': '82', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '56', 'groupId': 'BG000'}, {'value': '59', 'groupId': 'BG001'}, {'value': '54', 'groupId': 'BG002'}, {'value': '57', 'groupId': 'BG003'}, {'value': '226', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'FACTORIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 308}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-04', 'completionDateStruct': {'date': '2010-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-02-05', 'studyFirstSubmitDate': '2007-12-18', 'resultsFirstSubmitDate': '2013-01-23', 'studyFirstSubmitQcDate': '2007-12-18', 'lastUpdatePostDateStruct': {'date': '2018-03-06', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2013-04-17', 'studyFirstPostDateStruct': {'date': '2007-12-19', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2013-05-27', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2010-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Patient Well Being, as Determined by a Visual Analog Scale', 'timeFrame': 'Measured at 72 hours', 'description': 'Global Visual Analog Scale Scale Range 0-7200; higher score is better'}, {'measure': 'Change in Serum Creatinine', 'timeFrame': 'Measured at baseline and 72 hours'}], 'secondaryOutcomes': [{'measure': 'Change in Weight', 'timeFrame': 'baseline and 96 hours'}, {'measure': 'Proportion of Patients Free of Congestion', 'timeFrame': 'Measured at 72 hours'}, {'measure': 'Dyspnea, as Determined by Visual Analog Scales', 'timeFrame': 'Measured at 24 hours', 'description': 'Global Visual Analog Scale Scale Range 0-2400; higher score is better'}, {'measure': 'Change in Serum Creatinine', 'timeFrame': 'baseline and 24 hours'}, {'measure': 'Change in Cystatin C', 'timeFrame': 'baseline and 72 hours'}, {'measure': 'Change in Serum Creatinine', 'timeFrame': 'baseline and 48 hours'}, {'measure': 'Change in Serum Creatinine', 'timeFrame': 'baseline and 96 hours'}, {'measure': 'Change in Serum Creatinine', 'timeFrame': 'baseline and day 7'}, {'measure': 'Change in Serum Creatinine', 'timeFrame': 'baseline and day 60'}, {'measure': 'Patient Well Being, as Determined by a Visual Analog Scale', 'timeFrame': 'Measured at 24 hours', 'description': 'Global Visual Analog Scale Scale Range 0-2400; higher score is better'}, {'measure': 'Patient Well Being, as Determined by a Visual Analog Scale', 'timeFrame': '48 hours', 'description': 'Global Visual Analog Scale Scale Range 0-4800; higher score is better'}, {'measure': 'Dyspnea VAS', 'timeFrame': '48 hours', 'description': 'Dyspnea Visual Analog Scale Scale Range 0-4800; higher score is better'}, {'measure': 'Dyspnea VAS', 'timeFrame': '72 hours', 'description': 'Dyspnea Visual Analog Scale Scale Range 0-7200; higher score is better'}, {'measure': 'Change in Cystatin C', 'timeFrame': 'baseline and day 7'}, {'measure': 'Change in Cystatin C', 'timeFrame': 'baseline and day 60'}, {'measure': 'Change in Uric Acid', 'timeFrame': 'baseline and 72 hours'}, {'measure': 'Change in Uric Acid', 'timeFrame': 'baseline and day 7'}, {'measure': 'Change in Uric Acid', 'timeFrame': 'baseline and Day 60'}, {'measure': 'Change in B-type Natriuretic Peptide', 'timeFrame': 'baseline and 72 hours', 'description': 'Change in NTproBNP'}, {'measure': 'Change in NTproBNP', 'timeFrame': 'baseline and Day 7'}, {'measure': 'Change in NTproBNP', 'timeFrame': 'baseline and Day 60'}, {'measure': 'Presence of Cardiorenal Syndrome', 'timeFrame': 'Within 72 hours'}, {'measure': 'Treatment Failure', 'timeFrame': 'Within 72 hours', 'description': 'Treatment failure is defined as the patient met cardiorenal syndrome endpoint, worsening or persistent heart failure endpoint, patient died, or there was clinical evidence of overdiuresis requiring intervention within first 72 hours after randomization'}, {'measure': 'Net Fluid Loss', 'timeFrame': 'Through 24 hours'}, {'measure': 'Net Fluid Loss', 'timeFrame': 'Through 48 hours'}, {'measure': 'Net Fluid Loss', 'timeFrame': 'Through 72 hours'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Loop Diuretics', 'Furosemide', 'Fluid Overload', 'Cardio Renal Failure'], 'conditions': ['Heart Failure']}, 'referencesModule': {'references': [{'pmid': '21366472', 'type': 'RESULT', 'citation': "Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797-805. doi: 10.1056/NEJMoa1005419."}, {'pmid': '38775253', 'type': 'DERIVED', 'citation': 'Rasoul D, Zhang J, Farnell E, Tsangarides AA, Chong SC, Fernando R, Zhou C, Ihsan M, Ahmed S, Lwin TS, Bateman J, Hill RA, Lip GY, Sankaranarayanan R. Continuous infusion versus bolus injection of loop diuretics for acute heart failure. Cochrane Database Syst Rev. 2024 May 22;5(5):CD014811. doi: 10.1002/14651858.CD014811.pub2.'}, {'pmid': '27514750', 'type': 'DERIVED', 'citation': "Kelly JP, Cooper LB, Gallup D, Anstrom KJ, Chen HH, Redfield MM, O'Connor CM, Mentz RJ, Hernanadez AF, Felker GM. Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. Circ Heart Fail. 2016 Aug;9(8):e003048. doi: 10.1161/CIRCHEARTFAILURE.116.003048."}, {'pmid': '26927285', 'type': 'DERIVED', 'citation': 'de Denus S, Rouleau JL, Mann DL, Huggins GS, Cappola TP, Shah SH, Keleti J, Zada YF, Provost S, Bardhadi A, Phillips MS, Normand V, Mongrain I, Dube MP. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics J. 2017 Mar;17(2):192-200. doi: 10.1038/tpj.2016.4. Epub 2016 Mar 1.'}, {'pmid': '26041600', 'type': 'DERIVED', 'citation': 'Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015 Jul;8(4):741-8. doi: 10.1161/CIRCHEARTFAILURE.114.001957. Epub 2015 Jun 3.'}, {'pmid': '25543972', 'type': 'DERIVED', 'citation': "Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, AbouEzzeddine OF, Khazanie P, Redfield MM, Stevenson LW, O'Connor CM, Goldsmith SR, Bart BA, Anstrom KJ, Hernandez AF, Braunwald E, Felker GM. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2015 Feb;3(2):97-107. doi: 10.1016/j.jchf.2014.09.003. Epub 2014 Oct 31."}, {'pmid': '23250981', 'type': 'DERIVED', 'citation': "Kociol RD, McNulty SE, Hernandez AF, Lee KL, Redfield MM, Tracy RP, Braunwald E, O'Connor CM, Felker GM; NHLBI Heart Failure Network Steering Committee and Investigators. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail. 2013 Mar;6(2):240-5. doi: 10.1161/CIRCHEARTFAILURE.112.969246. Epub 2012 Dec 18."}, {'pmid': '23194486', 'type': 'DERIVED', 'citation': "Shah RV, McNulty S, O'Connor CM, Felker GM, Braunwald E, Givertz MM. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Am Heart J. 2012 Dec;164(6):862-8. doi: 10.1016/j.ahj.2012.08.019. Epub 2012 Oct 29."}]}, 'descriptionModule': {'briefSummary': 'Heart failure is a disorder in which the heart does not pump blood adequately. This can lead to several serious problems, including reduced blood flow throughout the body, congestion of blood in the veins and lungs, and fluid accumulation in various organs and limbs. Diuretics are often used to address the problem of fluid accumulation, but the optimal dose and the amount of time over which to administer each dose are unclear. This study will compare high and low doses of diuretics administered over longer and shorter periods of time to determine the safest and most effective combination.', 'detailedDescription': 'Heart failure is a common disorder in which the heart cannot pump enough blood to meet the needs of the rest of the body. Heart failure symptoms include shortness of breath, swelling, and fatigue. Standard treatment for the swelling associated with heart failure includes the use of diuretic medications, such as furosemide, which cause urination and the removal of excess fluids in the body. Although furosemide has been used to treat heart failure patients for many years, it is still unclear how much of the drug to use, and over what time period the drug should be given. This study will evaluate whether furosemide treatment is safer and more effective when the drug is given in high doses versus low doses and in two to three separate doses versus one continuous infusion.\n\nParticipants in this study will begin study procedures within the first 24 hours of their hospital admission for heart failure. Participants will be randomly assigned to receive one of the following four treatments: high dose furosemide via continuous intravenous (IV) infusion and placebo every 12 hours via IV bolus; low dose furosemide via continuous IV infusion and placebo every 12 hours via IV bolus; high dose furosemide every 12 hours via IV bolus and placebo via continuous IV infusion; and low dose furosemide every 12 hours via IV bolus and placebo via continuous IV infusion. Each participant will receive treatment for the first 72 hours of his or her hospital stay. Participants will answer questionnaires and undergo physical examinations and blood tests during the first 96 hours of hospitalization and again before hospital discharge or on Day 7, if that occurs first. Participants will be asked to return to their doctors 60 days following hospital discharge to evaluate their responses to treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Prior clinical diagnosis of heart failure that was treated with daily oral loop diuretics for at least 1 month\n* Current diagnosis of heart failure, as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema) AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular congestion on chest radiography)\n* Daily oral dose of furosemide between 80 mg and 240 mg (or equivalent)\n* Identified within 24 hours of hospital admission\n* Current treatment plan includes IV loop diuretics for at least 48 hours\n\nExclusion Criteria:\n\n* Brain natriuretic peptide (BNP) less than 250 mg/mL or N-terminal prohormone brain natriuretic peptide (NT-proBNP) less than 1000 mg/mL\n* Received IV vasoactive treatment or ultra-filtration therapy for heart failure since initial presentation\n* Treatment plan during current hospitalization includes IV vasoactive treatment or ultra-filtration for heart failure\n* Substantial diuretic response to pre-randomization diuretic dosing such that higher doses of diuretics would be medically inadvisable\n* Systolic blood pressure less than 90 mm Hg\n* Serum creatinine level greater than 3.0 mg/dL at baseline or currently undergoing renal replacement therapy\n* Hemodynamically significant arrhythmias\n* Acute coronary syndrome within 4 weeks prior to study entry\n* Active myocarditis\n* Hypertrophic obstructive cardiomyopathy\n* Severe stenotic valvular disease\n* Restrictive or constrictive cardiomyopathy\n* Complex congenital heart disease\n* Constrictive pericarditis\n* Non-cardiac pulmonary edema\n* Clinical evidence of digoxin toxicity\n* Need for mechanical hemodynamic support\n* Sepsis\n* Terminal illness (other than heart failure) with expected survival time of less than 1 year\n* History of adverse reaction to the study drugs\n* Use of IV iodinated radiocontrast material within 72 hours prior to study entry or planned during hospitalization\n* Enrollment or planned enrollment in another randomized clinical trial during this hospitalization\n* Inability to comply with planned study procedures'}, 'identificationModule': {'nctId': 'NCT00577135', 'briefTitle': 'Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)', 'organization': {'class': 'OTHER', 'fullName': 'Duke University'}, 'officialTitle': 'Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)', 'orgStudyIdInfo': {'id': 'Pro00017634'}, 'secondaryIdInfos': [{'id': 'U01HL084904-01', 'link': 'https://reporter.nih.gov/quickSearch/U01HL084904-01', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Q12 hour bolus', 'description': 'Furosemide-Q12 hour bolus', 'interventionNames': ['Drug: Furosemide-Low Intensification', 'Drug: Furosemide-High Intensification']}, {'type': 'EXPERIMENTAL', 'label': 'Continuous Infusion', 'description': 'Furosemide-Continuous Infusion', 'interventionNames': ['Drug: Furosemide-Low Intensification', 'Drug: Furosemide-High Intensification']}, {'type': 'EXPERIMENTAL', 'label': 'Low Intensification', 'description': 'Furosemide-Low Intensification', 'interventionNames': ['Drug: Furosemide-Q12 hour bolus', 'Drug: Furosemide-Continuous Infusion']}, {'type': 'EXPERIMENTAL', 'label': 'High Intensification', 'description': 'Furosemide-High Intensification', 'interventionNames': ['Drug: Furosemide-Q12 hour bolus', 'Drug: Furosemide-Continuous Infusion']}], 'interventions': [{'name': 'Furosemide-Q12 hour bolus', 'type': 'DRUG', 'otherNames': ['Loop diuretics'], 'description': 'Q12 hours bolus', 'armGroupLabels': ['High Intensification', 'Low Intensification']}, {'name': 'Furosemide-Continuous Infusion', 'type': 'DRUG', 'otherNames': ['Loop diuretic'], 'description': 'Continuous infusion', 'armGroupLabels': ['High Intensification', 'Low Intensification']}, {'name': 'Furosemide-Low Intensification', 'type': 'DRUG', 'otherNames': ['Loop diuretic'], 'description': '1x oral dose', 'armGroupLabels': ['Continuous Infusion', 'Q12 hour bolus']}, {'name': 'Furosemide-High Intensification', 'type': 'DRUG', 'otherNames': ['loop diuretic'], 'description': '2.5x oral dose', 'armGroupLabels': ['Continuous Infusion', 'Q12 hour bolus']}]}, 'contactsLocationsModule': {'locations': [{'zip': '30310', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Morehouse School of Medicine', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': "Brigham and Women's Hospital", 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '55415', 'city': 'Minneapolis', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Minnesota Heart Failure Network', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '27705', 'city': 'Durham', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Duke University Medical Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor College of Medicine', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '84107', 'city': 'Murray', 'state': 'Utah', 'country': 'United States', 'facility': 'University of Utah Health Sciences Center', 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'zip': '05401', 'city': 'Burlington', 'state': 'Vermont', 'country': 'United States', 'facility': 'University of Vermont - Fletcher Allen Health Care', 'geoPoint': {'lat': 44.47588, 'lon': -73.21207}}, {'zip': 'H1T - 1C8', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Montreal Heart Institute', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}], 'overallOfficials': [{'name': 'Kerry L. Lee, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Duke Clinical Research Institute'}, {'name': 'Eugene Braunwald, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Harvard University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Duke University', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Heart, Lung, and Blood Institute (NHLBI)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}